Evidence map›Paper›PMID 40266150›Full record

ArticleVaccines2025

Surface Display of Type 1 Fimbriae on

Shuli Sang, Rui Yu, Yunyun Mao, Yanfang Zhai, Chen Cao, Kai Li, Yiyan Guan, Haoxia Tao, Chunjie Liu, Yanchun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuli SangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Rui YuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.ORCID 0000-0002-6431-9737
Yunyun MaoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Yanfang ZhaiLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Chen CaoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Kai LiLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Yiyan GuanLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Haoxia TaoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Chunjie LiuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.
Yanchun WangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, 20 Dongda Street, Fengtai District, Beijing 100071, China.ORCID 0000-0002-0203-7312

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLive attenuated bacteria are promising candidates for mucosal vaccine delivery due to their ability to elicit robust immune responses. FimH is the adhesion protein of type 1 fimbriae, which is used as mucosal adjuvants. This study aims to develop a novel attenuated live bacterial vector via fimbriae recovery on

resultsFunctional type 1 fimbriae on pBAD-Fim/FWL01 were confirmed using TEM and mannose-sensitive agglutination assays. Transcriptome analysis, qRT-PCR, and ELISA assays revealed that pBAD-Fim/FWL01 significantly stimulated mouse macrophages to release cytokines IL-1α, IL-1β, IL-6, and IL-10, inducing an immune response. Orally administrated pBAD-Fim-trc-napA-His/FWL01 elicited significant mucosal and humoral immune responses.

conclusionsThe strain pBAD-Fim/FWL01, which expresses type 1 fimbriae, holds promise for development as an attenuated bacterial vaccine vehicle.

Indexed as

attenuated bacterial vectorShigella flexneritype 1 fimbriae

Identifiers

PMID40266150
PMCPMC11945882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.